Verition Fund Management
OVID icon

Verition Fund Management’s Ovid Therapeutics OVID Stock Holding History

Verition Fund Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-215,060
Closed -$67.1K – 3795
2025
Q1 		$67.1K Buy
215,060
+67,755
+46% +$41.7K ﹤0.01% 3182
2024
Q4 		$138K Buy
147,305
+72,430
+97% +$81K ﹤0.01% 3040
2024
Q3 		$88.4K Buy
+74,875
New +$78.2K ﹤0.01% 3012

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Verition Fund Management's OVID Position: Q2 2025 in Review

Verition Fund Management sold out of Ovid Therapeutics (OVID) in Q2 2025, closing a stake of 215,060 shares — an estimated $67.1K sold.

Verition Fund Management first reported a position in OVID in Q3 2024 and held it in 3 quarters. The position peaked at $138K in Q4 2024. 71 funds tracked by Wall St. Rank hold OVID as of Q2 2025.

  • Verition Fund Management reported no remaining Ovid Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Verition Fund Management sold 215,060 Ovid Therapeutics shares in Q2 2025, an estimated $67.1K.
  • Verition Fund Management first reported a position in Ovid Therapeutics in Q3 2024 and held it in 3 quarters.
  • Verition Fund Management's Ovid Therapeutics position peaked at $138K in Q4 2024.
  • 71 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.